Incyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress

Reuters

06-03

Incyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress

Incyte Corporation has announced the presentation of new data from its hematology/oncology portfolio, specifically highlighting its mutCALR-directed monoclonal antibody, INCA033989, at the 2025 European Hematology Association (EHA) Congress in Milan. The late-breaking oral presentation will focus on trial results of INCA033989, targeting anti-mutant calreticulin (mutCALR) in patients with essential thrombocythemia $(ET)$. The presentation is slated for June 15, 2025. Incyte will also host an analyst and investor event on the same day to discuss the mutCALR data, accessible via webcast on their website. The data reportedly demonstrates the antibody's potential as a disease-modifying agent for myeloproliferative neoplasms (MPNs).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602113126) on June 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540377097"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540377097\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540377097?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540377097","market":"us","top_or_hot":-1,"title":"Incyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced the presentation of new data from its hematology/oncology portfolio, specifically highlighting its mutCALR-directed monoclonal antibody, INCA033989, at the 2025 European Hematology Association (EHA) Congress in Milan. The late-breaking oral presentation will focus on trial results of INCA033989, targeting anti-mutant calreticulin (mutCALR) in patients with essential thrombocythemia <a href=\"https://laohu8.com/S/ET\">$(ET)$</a>. The presentation is slated for June 15, 2025. Incyte will also host an analyst and investor event on the same day to discuss the mutCALR data, accessible via webcast on their website. The data reportedly demonstrates the antibody's potential as a disease-modifying agent for myeloproliferative neoplasms (MPNs).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602113126) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-03 22:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced the presentation of new data from its hematology/oncology portfolio, specifically highlighting its mutCALR-directed monoclonal antibody, INCA033989, at the 2025 European Hematology Association (EHA) Congress in Milan. The late-breaking oral presentation will focus on trial results of INCA033989, targeting anti-mutant calreticulin (mutCALR) in patients with essential thrombocythemia <a href=\"https://laohu8.com/S/ET\">$(ET)$</a>. The presentation is slated for June 15, 2025. Incyte will also host an analyst and investor event on the same day to discuss the mutCALR data, accessible via webcast on their website. The data reportedly demonstrates the antibody's potential as a disease-modifying agent for myeloproliferative neoplasms (MPNs).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602113126) on June 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL9ZKpPH:1","article_id":"2540377097","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540377097","pubTimestamp":1748961033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire  on June 03, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4550":"红杉资本持仓","BK4588":"碎股","BK4139":"生物科技","INCY":"因塞特医疗","BK4532":"文艺复兴科技持仓"},"translate_title":"Incyte Corporation在EHA 2025大会上公布了新型mutCALR导向单克隆抗体的有希望的最新数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"Incyte Corporation Unveils Promising Late-Breaking Data for Novel mutCALR-Directed Monoclonal Antibody at EHA 2025 Congress\n    \n\n        Incyte Corporation has announced the presentation of new data from its hematology/oncology portfolio, specifically highlighting its mutCALR-directed monoclonal antibody, INCA033989, at the 2025 European Hematology Association (EHA) Congress in Milan. The late-breaking oral presentation will focus on trial results of INCA033989, targeting anti-mutant calreticulin (mutCALR) in patients with essential thrombocythemia $(ET)$. The presentation is slated for June 15, 2025. Incyte will also host an analyst and investor event on the same day to discuss the mutCALR data, accessible via webcast on their website. The data reportedly demonstrates the antibody's potential as a disease-modifying agent for myeloproliferative neoplasms (MPNs).\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250602113126) on June 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}